{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:29:55Z","timestamp":1786494595191,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515012703"],"award-info":[{"award-number":["2025A1515012703"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515012659"],"award-info":[{"award-number":["2023A1515012659"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010302"],"award-info":[{"award-number":["2023A1515010302"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025B1515020089"],"award-info":[{"award-number":["2025B1515020089"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203026"],"award-info":[{"award-number":["82203026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473421"],"award-info":[{"award-number":["82473421"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372833"],"award-info":[{"award-number":["82372833"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203798"],"award-info":[{"award-number":["82203798"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New Talent Program of The First Affiliated Hospital, Sun Yat-sen Universit"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncolytic virotherapy has shown promise for various cancers, but its application in osteosarcoma (OS) remains underexplored. This study provides evidence that M1, a natural Getah-like alphavirus, exerts oncolytic activity against OS. We demonstrate that OS cells exhibit heightened sensitivity to M1 infection, with its anti-tumor effects not solely dependent on the canonical ER stress-induced apoptosis. Proteomic and ChIP-seq analyses show the DNA-directed RNA polymerase II subunit RPB1 contributes to oncogenic super-enhancer activity and serves as a direct target of M1-mediated regulation. The oncolytic potency correlated positively with the transcriptional dependency on RPB1 within super-enhancer regions. Mechanistically, the viral non-structural protein NSP2 disrupts super-enhancer activity by recruiting the CUL2-RBX1-ELOC complex, which triggers K63-linked ubiquitination and degradation of RPB1. Together, these findings uncover a previously unrecognized mechanism underlying M1 activity in osteosarcoma, support further preclinical evaluation of M1 in this setting, and identify RPB1 as a candidate biomarker for virotherapy response.<\/jats:p>","DOI":"10.1038\/s41467-026-75013-9","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:05:21Z","timestamp":1782925521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Alphavirus M1 disrupts super-enhancer-driven oncogenic transcription via non-structural protein NSP2 in osteosarcoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8859-9542","authenticated-orcid":false,"given":"Jiajun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-1101","authenticated-orcid":false,"given":"Jiayu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4378-7646","authenticated-orcid":false,"given":"Jiankai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9143-5733","authenticated-orcid":false,"given":"Wenbo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-0965","authenticated-orcid":false,"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8366-3480","authenticated-orcid":false,"given":"Junqiang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-6129","authenticated-orcid":false,"given":"Weihai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"75013_CR1","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","volume":"33","author":"MS Isakoff","year":"2015","unstructured":"Isakoff, M. S., Bielack, S. S., Meltzer, P. & Gorlick, R. Osteosarcoma: current treatment and a collaborative pathway to success. J. Clin. Oncol. 33, 3029\u20133035 (2015).","journal-title":"J. Clin. Oncol."},{"key":"75013_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird, H. C. et al. Osteosarcoma. Nat. Rev. Dis. Prim. 8, 77 (2022).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"75013_CR3","first-page":"7","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"75013_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","volume":"18","author":"J Gill","year":"2021","unstructured":"Gill, J. & Gorlick, R. Advancing therapy for osteosarcoma. Nat. Rev. Clin. Oncol. 18, 609\u2013624 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"75013_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"SE Lawler","year":"2017","unstructured":"Lawler, S. E., Speranza, M. C., Cho, C. F. & Chiocca, E. A. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 3, 841\u2013849 (2017).","journal-title":"JAMA Oncol."},{"key":"75013_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","volume":"6","author":"J Raja","year":"2018","unstructured":"Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A. & Kim, H. S. Oncolytic virus immunotherapy: future prospects for oncology. J. Immunother. Cancer 6, 140 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"75013_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689\u2013706 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"75013_CR8","doi-asserted-by":"crossref","unstructured":"N. Macedo, D. M. Miller, R. Haq, H. L. Kaufman. (2020). Clinical landscape of oncolytic virus research in 2020. J. Immunother. Cancer 8, 1486 (2020).","DOI":"10.1136\/jitc-2020-001486"},{"key":"75013_CR9","doi-asserted-by":"publisher","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","volume":"5","author":"J Pol","year":"2016","unstructured":"Pol, J., Kroemer, G. & Galluzzi, L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology 5, e1115641 (2016).","journal-title":"Oncoimmunology"},{"key":"75013_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39156-3","volume":"14","author":"L Guo","year":"2023","unstructured":"Guo, L. et al. Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile. Nat. Commun. 14, 3410 (2023).","journal-title":"Nat. Commun."},{"key":"75013_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1089\/hum.2020.271","volume":"32","author":"J Cai","year":"2021","unstructured":"Cai, J. & Yan, G. The identification and development of a novel oncolytic virus: alphavirus M1. Hum. Gene Ther. 32, 138\u2013149 (2021).","journal-title":"Hum. Gene Ther."},{"key":"75013_CR12","doi-asserted-by":"publisher","first-page":"E4504","DOI":"10.1073\/pnas.1408759111","volume":"111","author":"Y Lin","year":"2014","unstructured":"Lin, Y. et al. Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc. Natl. Acad. Sci. USA 111, E4504\u2013E4512 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75013_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s12250-020-00339-7","volume":"36","author":"J Dan","year":"2021","unstructured":"Dan, J. et al. Visualization of the oncolytic alphavirus M1 life cycle in cancer cells. Virol. Sin. 36, 655\u2013666 (2021).","journal-title":"Virol. Sin."},{"key":"75013_CR14","doi-asserted-by":"publisher","first-page":"101229","DOI":"10.1016\/j.xcrm.2023.101229","volume":"4","author":"J Dan","year":"2023","unstructured":"Dan, J. et al. Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. Cell Rep. Med. 4, 101229 (2023).","journal-title":"Cell Rep. Med."},{"key":"75013_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-022-00921-3","volume":"7","author":"D Song","year":"2022","unstructured":"Song, D. et al. Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors. Signal Transduct. Target. Ther. 7, 100 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"75013_CR16","doi-asserted-by":"crossref","unstructured":"H. Zhang, et al. Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci. Transl. Med. 9, 7996 (2017).","DOI":"10.1126\/scitranslmed.aam7996"},{"key":"75013_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2020.12.018","volume":"502","author":"S Sun","year":"2021","unstructured":"Sun, S. et al. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Cancer Lett. 502, 9\u201324 (2021).","journal-title":"Cancer Lett."},{"key":"75013_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44872-5","volume":"15","author":"X Zhai","year":"2024","unstructured":"Zhai, X. et al. LDLR is used as a cell entry receptor by multiple alphaviruses. Nat. Commun. 15, 622 (2024).","journal-title":"Nat. Commun."},{"key":"75013_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02033-8","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu, S. et al. Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets. Mol. Cancer 23, 122 (2024).","journal-title":"Mol. Cancer"},{"key":"75013_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"75013_CR21","doi-asserted-by":"publisher","first-page":"11847","DOI":"10.1080\/21655979.2021.1999372","volume":"12","author":"J Jiang","year":"2021","unstructured":"Jiang, J., Wang, W., Xiang, W., Jiang, L. & Zhou, Q. The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSV\u039451 via aggravating endoplasmic reticulum stress. Bioengineered 12, 11847\u201311857 (2021).","journal-title":"Bioengineered"},{"key":"75013_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jgm.2893","volume":"18","author":"X Jia","year":"2016","unstructured":"Jia, X., Chen, Y., Zhao, X., Lv, C. & Yan, J. Oncolytic vaccinia virus inhibits human hepatocellular carcinoma MHCC97-H cell proliferation via endoplasmic reticulum stress, autophagy and Wnt pathways. J. Gene Med. 18, 211\u2013219 (2016).","journal-title":"J. Gene Med."},{"key":"75013_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41392-023-01603-4","volume":"8","author":"B Cui","year":"2023","unstructured":"Cui, B. et al. Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors. Signal Transduct. Target. Ther. 8, 366 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"75013_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-023-02848-1","volume":"42","author":"G Wang","year":"2023","unstructured":"Wang, G. et al. The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors. J. Exp. Clin. Cancer Res. 42, 284 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"75013_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101895","volume":"8","author":"B Lu","year":"2021","unstructured":"Lu, B. et al. Pharmacological inhibition of core regulatory circuitry liquid-liquid phase separation suppresses metastasis and chemoresistance in osteosarcoma. Adv. Sci. 8, e2101895 (2021).","journal-title":"Adv. Sci."},{"key":"75013_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.598660","volume":"8","author":"Z Ouyang","year":"2020","unstructured":"Ouyang, Z. et al. Construction of a five-super-enhancer-associated-genes prognostic model for osteosarcoma patients. Front. Cell. Dev. Biol. 8, 598660 (2020).","journal-title":"Front. Cell. Dev. Biol."},{"key":"75013_CR27","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1158\/1078-0432.CCR-19-1418","volume":"26","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Targeting super-enhancer-associated oncogenes in osteosarcoma with THZ2, a covalent CDK7 inhibitor. Clin. Cancer Res. 26, 2681\u20132692 (2020).","journal-title":"Clin. Cancer Res."},{"key":"75013_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405907","volume":"11","author":"G Huang","year":"2024","unstructured":"Huang, G. et al. SNPs give LACTB oncogene-like functions and prompt tumor progression via dual-regulating p53. Adv. Sci. 11, e2405907 (2024).","journal-title":"Adv. Sci."},{"key":"75013_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307\u2013319 (2013).","journal-title":"Cell"},{"key":"75013_CR30","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934\u2013947 (2013).","journal-title":"Cell"},{"key":"75013_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-0108-z","volume":"4","author":"F Tang","year":"2020","unstructured":"Tang, F., Yang, Z., Tan, Y. & Li, Y. Super-enhancer function and its application in cancer targeted therapy. npj Precis. Oncol. 4, 2 (2020).","journal-title":"npj Precis. Oncol."},{"key":"75013_CR32","doi-asserted-by":"publisher","first-page":"6343","DOI":"10.1093\/nar\/gkac483","volume":"50","author":"L Lao","year":"2022","unstructured":"Lao, L. et al. ARMC5 is part of an RPB1-specific ubiquitin ligase implicated in adrenal hyperplasia. Nucleic Acids Res 50, 6343\u20136367 (2022).","journal-title":"Nucleic Acids Res"},{"key":"75013_CR33","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.molcel.2022.02.027","volume":"82","author":"EV Rusilowicz-Jones","year":"2022","unstructured":"Rusilowicz-Jones, E. V., Urb\u00e9, S. & Clague, M. J. Protein degradation on the global scale. Mol. Cell 82, 1414\u20131423 (2022).","journal-title":"Mol. Cell"},{"key":"75013_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41584-022-00778-4","volume":"18","author":"DB Beck","year":"2022","unstructured":"Beck, D. B., Werner, A., Kastner, D. L. & Aksentijevich, I. Disorders of ubiquitylation: unchained inflammation. Nat. Rev. Rheumatol. 18, 435\u2013447 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"75013_CR35","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fcell.2019.00392","volume":"7","author":"M van Huizen","year":"2019","unstructured":"van Huizen, M. & Kikkert, M. The role of atypical ubiquitin chains in the regulation of the antiviral innate immune response. Front. Cell. Dev. Biol. 7, 392 (2019).","journal-title":"Front. Cell. Dev. Biol."},{"key":"75013_CR36","doi-asserted-by":"publisher","first-page":"6896","DOI":"10.1016\/j.cell.2024.09.008","volume":"187","author":"H Li","year":"2024","unstructured":"Li, H. et al. Rift valley fever virus coordinates the assembly of a programmable E3 ligase to promote viral replication. Cell 187, 6896\u20136913.e15 (2024).","journal-title":"Cell"},{"key":"75013_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2403235121","volume":"121","author":"W Ren","year":"2024","unstructured":"Ren, W. et al. Zika virus NS5 protein inhibits type I interferon signaling via CRL3 E3 ubiquitin ligase-mediated degradation of STAT2. Proc. Natl. Acad. Sci. USA 121, e2403235121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75013_CR38","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732\u2013736 (2009).","journal-title":"Nature"},{"key":"75013_CR39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev-biochem-090120-013613","volume":"90","author":"JW Harper","year":"2021","unstructured":"Harper, J. W. & Schulman, B. A. Cullin-RING ubiquitin ligase regulatory circuits: a quarter century beyond the F-box hypothesis. Annu. Rev. Biochem. 90, 403\u2013429 (2021).","journal-title":"Annu. Rev. Biochem."},{"key":"75013_CR40","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.str.2017.04.009","volume":"25","author":"TAF Cardote","year":"2017","unstructured":"Cardote, T. A. F., Gadd, M. S. & Ciulli, A. Crystal structure of the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex. Structure 25, 901\u2013911.e3 (2017).","journal-title":"Structure"},{"key":"75013_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2020.04.003","volume":"67","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y., Xiong, X. & Sun, Y. Cullin-RING Ligase 5: functional characterization and its role in human cancers. Semin. Cancer Biol. 67, 61\u201379 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"75013_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105476","volume":"209","author":"AM Skidmore","year":"2023","unstructured":"Skidmore, A. M. & Bradfute, S. B. The life cycle of the alphaviruses: from an antiviral perspective. Antivir. Res 209, 105476 (2023).","journal-title":"Antivir. Res"},{"key":"75013_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/bs.aivir.2021.07.003","volume":"111","author":"T Ahola","year":"2021","unstructured":"Ahola, T., McInerney, G. & Merits, A. Alphavirus RNA replication in vertebrate cells. Adv. Virus Res. 111, 111\u2013156 (2021).","journal-title":"Adv. Virus Res."},{"key":"75013_CR44","doi-asserted-by":"crossref","unstructured":"Lundstrom K. Self-replicating alphaviruses: from pathogens to therapeutic agents. Viruses 16, 1762 (2024).","DOI":"10.3390\/v16111762"},{"key":"75013_CR45","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.str.2006.07.010","volume":"14","author":"AT Russo","year":"2006","unstructured":"Russo, A. T., White, M. A. & Watowich, S. J. The crystal structure of the venezuelan equine encephalitis alphavirus nsP2 protease. Structure 14, 1449\u20131458 (2006).","journal-title":"Structure"},{"key":"75013_CR46","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1099\/jgv.0.000249","volume":"96","author":"JC Rupp","year":"2015","unstructured":"Rupp, J. C., Sokoloski, K. J., Gebhart, N. N. & Hardy, R. W. Alphavirus RNA synthesis and non-structural protein functions. J. Gen. Virol. 96, 2483\u20132500 (2015).","journal-title":"J. Gen. Virol."},{"key":"75013_CR47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma, R., Li, Z., Chiocca, E. A., Caligiuri, M. A. & Yu, J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer 9, 122\u2013139 (2023).","journal-title":"Trends Cancer"},{"key":"75013_CR48","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/mt.2014.243","volume":"23","author":"TP Cripe","year":"2015","unstructured":"Cripe, T. P. et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol. Ther. 23, 602\u2013608 (2015).","journal-title":"Mol. Ther."},{"key":"75013_CR49","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin, D., Shen, Y. & Liang, T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct. Target Ther. 8, 156 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"75013_CR50","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","volume":"386","author":"J G\u00e1llego P\u00e9rez-Larraya","year":"2022","unstructured":"G\u00e1llego P\u00e9rez-Larraya, J. et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma. N. Engl. J. Med. 386, 2471\u20132481 (2022).","journal-title":"N. Engl. J. Med."},{"key":"75013_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25506-6","volume":"12","author":"K Das","year":"2021","unstructured":"Das, K. et al. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity. Nat. Commun. 12, 5195 (2021).","journal-title":"Nat. Commun."},{"key":"75013_CR52","doi-asserted-by":"publisher","first-page":"6812","DOI":"10.1073\/pnas.1701002114","volume":"114","author":"J Cai","year":"2017","unstructured":"Cai, J. et al. Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics. Proc. Natl. Acad. Sci. Usa. 114, 6812\u20136817 (2017).","journal-title":"Proc. Natl. Acad. Sci. Usa."},{"key":"75013_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.864781","volume":"9","author":"K Lundstrom","year":"2022","unstructured":"Lundstrom, K. Alphaviruses in cancer therapy. Front. Mol. Biosci. 9, 864781 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"75013_CR54","doi-asserted-by":"crossref","unstructured":"Pampeno, C., Opp, S., Hurtado, A., Meruelo, D. Sindbis virus vaccine platform: a promising oncolytic virus-mediated approach for ovarian cancer treatment. Int. J. Mol. Sci. 25, 2925 (2024).","DOI":"10.3390\/ijms25052925"},{"key":"75013_CR55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41417-022-00435-8","volume":"30","author":"P Aliahmad","year":"2023","unstructured":"Aliahmad, P., Miyake-Stoner, S. J., Geall, A. J. & Wang, N. S. Next generation self-replicating RNA vectors for vaccines and immunotherapies. Cancer Gene Ther. 30, 785\u2013793 (2023).","journal-title":"Cancer Gene Ther."},{"key":"75013_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04902-8","volume":"22","author":"G Huang","year":"2024","unstructured":"Huang, G. et al. Prognostic and predictive value of super-enhancer-derived signatures for survival and lung metastasis in osteosarcoma. J. Transl. Med. 22, 88 (2024).","journal-title":"J. Transl. Med."},{"key":"75013_CR57","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1158\/2767-9764.CRC-22-0060","volume":"2","author":"KA Blum","year":"2022","unstructured":"Blum, K. A. et al. A phase I study of pelabresib (CPI-0610), a small-molecule inhibitor of BET proteins, in patients with relapsed or refractory lymphoma. Cancer Res. Commun. 2, 795\u2013805 (2022).","journal-title":"Cancer Res. Commun."},{"key":"75013_CR58","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41417-021-00375-9","volume":"29","author":"OA Kharenko","year":"2022","unstructured":"Kharenko, O. A., Patel, R. G., Calosing, C. & van der Horst, E. H. Combination of ZEN-3694 with CDK4\/6 inhibitors reverses acquired resistance to CDK4\/6 inhibitors in ER-positive breast cancer. Cancer Gene Ther. 29, 859\u2013869 (2022).","journal-title":"Cancer Gene Ther."},{"key":"75013_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40061-y","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes, R. C. et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a phase I study of the CDK7-inhibitor samuraciclib. Nat. Commun. 14, 4444 (2023).","journal-title":"Nat. Commun."},{"key":"75013_CR60","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1021\/acs.jmedchem.0c01487","volume":"64","author":"P Tang","year":"2021","unstructured":"Tang, P., Zhang, J., Liu, J., Chiang, C. M. & Ouyang, L. Targeting bromodomain and extraterminal proteins for drug discovery: from current progress to technological development. J. Med. Chem. 64, 2419\u20132435 (2021).","journal-title":"J. Med. Chem."},{"key":"75013_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.128108","volume":"44","author":"MD Hill","year":"2021","unstructured":"Hill, M. D. et al. Development of BET inhibitors as potential treatments for cancer: a search for structural diversity. Bioorg. Med. Chem. Lett. 44, 128108 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"75013_CR62","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11262-007-0110-3","volume":"35","author":"JS Wen","year":"2007","unstructured":"Wen, J. S. et al. Genomic analysis of a Chinese isolate of getah-like virus and its phylogenetic relationship with other alphaviruses. Virus Genes 35, 597\u2013603 (2007).","journal-title":"Virus Genes"},{"key":"75013_CR63","doi-asserted-by":"publisher","first-page":"9798","DOI":"10.1128\/JVI.78.18.9798-9806.2004","volume":"78","author":"A Billecocq","year":"2004","unstructured":"Billecocq, A. et al. NSs protein of rift valley fever virus blocks interferon production by inhibiting host gene transcription. J. Virol. 78, 9798\u20139806 (2004).","journal-title":"J. Virol."},{"key":"75013_CR64","doi-asserted-by":"publisher","first-page":"9667","DOI":"10.1128\/JVI.00822-06","volume":"80","author":"VH L\u00e9onard","year":"2006","unstructured":"L\u00e9onard, V. H., Kohl, A., Hart, T. J. & Elliott, R. M. Interaction of bunyamwera orthobunyavirus NSs protein with mediator protein MED8: a mechanism for inhibiting the interferon response. J. Virol. 80, 9667\u20139675 (2006).","journal-title":"J. Virol."},{"key":"75013_CR65","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1074\/jbc.M110.154799","volume":"286","author":"P Verbruggen","year":"2011","unstructured":"Verbruggen, P. et al. Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II. J. Biol. Chem. 286, 3681\u20133692 (2011).","journal-title":"J. Biol. Chem."},{"key":"75013_CR66","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1745-7254.2008.00756.x","volume":"29","author":"CY Zou","year":"2008","unstructured":"Zou, C. Y. et al. Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases. Acta Pharmacol. Sin. 29, 325\u2013332 (2008).","journal-title":"Acta Pharmacol. Sin."},{"key":"75013_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2021.100378","volume":"29","author":"Z Fan","year":"2021","unstructured":"Fan, Z. et al. Establishment and characterization of a highly metastatic human osteosarcoma cell line from osteosarcoma lung metastases. J. Bone Oncol. 29, 100378 (2021).","journal-title":"J. Bone Oncol."},{"key":"75013_CR68","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/hum.2020.273","volume":"32","author":"W Zhu","year":"2021","unstructured":"Zhu, W. et al. Real-time visualization and quantification of oncolytic M1 virus in vitro and in vivo. Hum. Gene Ther. 32, 158\u2013165 (2021).","journal-title":"Hum. Gene Ther."},{"key":"75013_CR69","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","volume":"151","author":"CY Lin","year":"2012","unstructured":"Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56\u201367 (2012).","journal-title":"Cell"},{"key":"75013_CR70","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp, R. L., Dolled-Filhart, M. & Rimm, D. L. X-Tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10, 7252\u20137259 (2004).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75013-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75013-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75013-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:04:22Z","timestamp":1786493062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75013-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75013"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75013-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.-M.Y. and W.-B.Z. hold equity interests in Guangzhou Virotech Pharmaceutical Co., Ltd. G.-M.Y. serves as Chairperson of the company, W.-B.Z. and J.-K.L. serve on its Board of Directors. W.-B.Z., Y.L., J.-K.L. and J.C. serve as part-time scientific advisors to this company. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8208"}}